Abbott Laboratories (NYSE:ABT) currently has a daily average trading volume of 5.71M but it saw 4409683 shares traded in last market. With a market cap of 193.09B USD, the company’s current market price of $111.28 came falling about -0.66 while comparing to the previous closing price of $112.02. In past 52 weeks, the stock remained buoying in the range of price level as high as $121.64 and as low as $89.67.
Taking a look at 20-day trading activity of Abbott Laboratories (ABT) gives us an average price of $114.99, while its current price level is -8.52% below from 52-week high level whereas it is 24.09% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $114.99 while that of 200 days or SMA-200 reads an average of $106.58. A closer look into the stock’s movement over the week reveals that its volatility is standing at 1.33% during that period while stretching the period over a month that increases to 1.64%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 39.15 which implies that the stock is in neutral territory.
Morgan Stanley downgraded its recommendation for the stock as a “Equal-Weight” from “Overweight” on May 30, 2023 while assigning a price target of $112. Wolfe Research issued its recommendations for the stock as it reiterated the price target for the stock in the range of between $107 and $103.
Over the week, ABT’s stock price is moving -0.20% down while it is -7.30% when we observe its performance for the past one month. Year-to-date it is 1.10% up and over the past year, the stock is showing an upside performance of 9.90%.
The latest quarterly earnings report issued by the company was for quarter ended 12/30/2023, when its quarterly earnings per share (EPS) of $1.19 beat the consensus estimate of $1.19 for the same. For ABT, analysts are forecasting an EPS-growth rate of 3.60% for current year and estimate for EPS growth in next year is 10.70%. In next quarter, company is expected to be making quarterly sales of $10.49 billion as analysts are expecting the sales for current fiscal year at $42.01 billion and seeing the company making $45.01 billion in sales next year. Moreover, analysts are in estimates of $9.89 billion for current-quarter revenue.
Currently, Abbott Laboratories’s total number of outstanding shares is 1.73B with 0.54% of that held by the insiders while 77.02% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at 10.73% and return on equity (ROE) at 15.15%. It has a price to earnings ratio (P/E ratio) of 34.08 while having a 21.63 of forward P/E ratio. Stock’s beta reads 0.74. Stock has a price to book (P/B) ratio of 5.00 while price to sale or P/S ratio amounts to 4.81. Its return on asset (ROA) is 7.72% on average.
